Article

Parasympathetic Paragangliomas Are Part of the Von Hippel-Lindau Syndrome

Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands.
The Journal of Clinical Endocrinology and Metabolism (Impact Factor: 6.31). 10/2009; 94(11):4367-71. DOI: 10.1210/jc.2009-1479
Source: PubMed

ABSTRACT Von Hippel-Lindau (VHL) disease, caused by germline mutations in the VHL gene, is a hereditary tumor syndrome manifested by hemangioblastomas, clear cell renal cell carcinomas, and pheochromocytomas. In addition, a multitude of other rare tumors, including parasympathetic paragangliomas, can occur and even be the sole manifestation of VHL disease. The VHL gene is a bona fide tumor suppressor gene with biallelic inactivation contributing to tumor formation. However, in parasympathetic paragangliomas occurring in VHL disease, biallelic inactivation of the VHL gene has not been demonstrated to date.
The head and neck paragangliomas of two VHL patients were analyzed for mutations by direct sequencing of the VHL gene. In addition loss of heterozygosity analysis was performed for three microsatellite loci near the VHL gene. To rule out other underlying genetic causes of the parasympathetic paragangliomas, mutation analysis of the SDHB, SDHC, and SDHD genes was also performed.
Apart from germline VHL mutations, no additional mutations were found in the paraganglioma-related tumor suppressor genes SDHB, SDHC, and SDHD. Analysis of paraganglioma tissue revealed loss of the VHL wild-type allele in both tumors, indicating that in these tumors biallelic VHL gene inactivation occurred.
These findings indicate that parasympathetic paragangliomas in VHL disease, although rare, are part of the syndrome and related to VHL gene inactivation. Clinicians should be aware of the potential occurrence of parasympathetic paragangliomas in VHL disease.

0 Followers
 · 
120 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Los paragangliomas cervicales son tumores infrecuentes (menos del 0,01% de los tumores del ser humano). Algunas formas son esporádicas, mientras que otras son hereditarias. Estas últimas se relacionan con una mutación del gen que codifica la succinato deshidrogenasa, una enzima importante del ciclo de Krebs. La comprensión de la fisiopatología de estos tumores ha permitido elaborar un modelo tumoral original. El diagnóstico debe establecerse mediante las pruebas de imagen modernas, asociando la tomografía computarizada (TC) con la resonancia magnética (RM). Su tratamiento es medicoquirúrgico. Debe ser pluridisciplinario, con la participación de genetistas, cirujanos y radioterapeutas. La cirugía de resección es el único tratamiento radical, pero sus secuelas pueden ser considerables. La radioterapia es una alternativa. También puede optarse por la abstención terapéutica y la vigilancia.
    02/2014; 43(1):1–16. DOI:10.1016/S1632-3475(14)66712-6
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Paragangliomas are rare neuroendocrine tumors that arise in the sympathetic or parasympathetic nervous system. Sympathetic paragangliomas are mainly found in the adrenal medulla (designated pheochromocytomas) but may also have a thoracic, abdominal, or pelvic localization. Parasympathetic paragangliomas are generally located at the head or neck. Knowledge concerning the familial forms of paragangliomas has greatly improved in recent years. Additionally to the genes involved in the classical syndromic forms: VHL gene (von Hippel-Lindau), RET gene (Multiple Endocrine Neoplasia type 2), and NF1 gene (Neurofibromatosis type 1), 10 novel genes have so far been implicated in the occurrence of paragangliomas/pheochromocytomas: SDHA, SDHB, SDHC, SDHD, SDHAF2, TMEM127, MAX, EGLN1, HIF2A, and KIF1B. It is currently accepted that about 35% of the paragangliomas cases are due to germline mutations in one of these genes. Furthermore, somatic mutations of RET, VHL, NF1, MAX, HIF2A, and H-RAS can also be detected. The identification of the mutation responsible for the paraganglioma/pheochromocytoma phenotype in a patient may be crucial in determining the treatment and allowing specific follow-up guidelines, ultimately leading to a better prognosis. Herein, we summarize the most relevant aspects regarding the genetics and clinical aspects of the syndromic and nonsyndromic forms of pheochromocytoma/paraganglioma aiming to provide an algorithm for genetic testing.
    International Journal of Endocrinology 05/2014; 2014:794187. DOI:10.1155/2014/794187 · 1.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: I paragangliomi cervicali sono dei tumori rari (meno dello 0,01% dei tumori umani); alcune forme sono di comparsa sporadica, mentre altre sono ereditarie. Le forme ereditarie sono associate a una mutazione del gene che codifica per la succinato deidrogenasi, enzima importante del ciclo di Krebs. La comprensione della fisiopatologia di questi tumori ha permesso di elaborare un modello tumorale originale. La diagnosi deve essere posta grazie ai mezzi di diagnostica per immagini moderna, che associa tomografia computerizzata (TC) e risonanza magnetica (RM). Il loro trattamento è medicochirurgico. Esso deve essere pluridisciplinare, associando genetisti, chirurghi e radioterapisti. La chirurgia di exeresi è il solo trattamento radicale, ma le sequele possono essere importanti. La radioterapia è un’alternativa e possono essere presi in considerazione anche l’astensione terapeutica e il monitoraggio.
    06/2014; 13(2):1–15. DOI:10.1016/S1639-870X(14)66952-X